6:10 AM ET
8-K
Deal Termination
Sagimet Biosciences Deal Termination with Leerink Partners LLC
Sagimet Biosciences has suspended and terminated its at-the-market (ATM) offering prospectus supplement related to its Series A common stock. The company will not make any further sales under the sales agreement with Leerink Partners LLC until a new prospectus or registration statement is filed. The filing also included an updated investor presentation and clinical trial results for denifanstat in acne vulgaris.
- Counterparty
- Leerink Partners LLC